A fixed-dose combination antihypertensive medication containing an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. It provides effective blood pressure control in patients requiring triple therapy, reducing cardiovascular risks associated with uncontrolled hypertension.

Indications:
- Management of essential hypertension in patients not adequately controlled with dual therapy.
- Reduction of blood pressure to help prevent complications such as stroke, heart attack, and kidney damage.
- Suitable for patients who benefit from the convenience of a single-tablet triple combination.

Main Active Ingredients:
- Amlodipine 5 mg.
- Valsartan 160 mg.
- Hydrochlorothiazide 25 mg.

Precautions:
- Contraindicated in patients with hypersensitivity to any component.
- Avoid in severe hepatic impairment, severe renal impairment, or anuria.
- Not recommended during pregnancy (risk of fetal toxicity) or breastfeeding.
- Monitor electrolytes (especially potassium, sodium) and kidney function regularly.
- Use with caution in patients with:
- Heart failure or left ventricular dysfunction.
- Severe dehydration or volume depletion.
- Gout or hyperuricemia.
- Hepatic or renal impairment.
- Avoid excessive alcohol intake, which can potentiate blood pressure lowering.

Side Effects:
- Hypokalemia.
- Hyponatremia
- Hyperuricemia .
- Nausea
- Abdominal pain
- Diarrhea.
- Hypotension
- Orthostatic hypotension.
- Angioedema.
- Renal dysfunction.
- Electrolyte disturbances.
- Severe hypotension.
- Hypersensitivity reactions.

Drug–Drug Interactions:
- Potassium supplements, potassium-sparing diuretics, ACE inhibitors, ARBs.
- NSAIDs.
- Lithium.
- Other antihypertensives.
- Corticosteroids or ACTH.
- Alcohol, barbiturates, narcotics.
- Antidiabetic drugs.